9 小时on MSN
MindRank in phase 3 trial with China’s first AI-assisted new drug, cutting R&D costs by 60%
The company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029 Hangzhou-based ...
Jacobin on MSNOpinion
Killer Robots and the Fetish of Automation
The fetish of automation masks the commodification of combat judgment. Corporate software reshapes war while preserving just ...
Expect the unexpected, the saying goes, and that was certainly true in 2025. President Donald Trump was a major source of global and domestic disruption, but the year’s instability was also driven by ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果